Disease specific characteristics of fetal epigenetic markers for non-invasive prenatal testing of trisomy 21

BMC Medical Genomics

Table 5 Ct values of EPs by qPCR

EP		Placenta		Blood		Pvalue	Ct_MBDof cff-DNA (n = 20)	Pvalue
EP		Trisomy 21 (n = 11)	Normal (n = 14)	Pregnant (n = 16)	Non-pregnant (n = 6)	Pvalue	Ct_MBDof cff-DNA (n = 20)	Pvalue
EP6
	Ct_input	22.3±0.4	23.4±1.5	23.1±2.3	22.3±0.1	0.364	29.4 ±1.6^†	0.021
	Ct_MBD	20.9±0.9^a,b	20.9±1.0^c,d	29.3±1.1	29.1±2.3	<0.001
	ΔCt	1.5±0.9^a,b	2.5±0.9^c,d	−6.2±2.2	−6.7±2.4	<0.001
EP7
	Ct_input	22.8±0.9	24.8±2.5	24.0±2.7	21.8±0.6	0.143	29.5±1.5^#
	Ct_MBD	20.6±0.6^a,b	21.4±0.8^c,d	29.3±0.9	27.4±1.7	<0.001
	ΔCt	2.2±1.1^a,b	3.4±2.2^c,d	−5.3±2.9	−5.6±1.2	<0.001
EP9
	Ct_input	20.7±0.2	21.9±0.6	21.2±0.6	22.9±0.1	0.243	34.8±4.6
	Ct_MBD	28.8±0.6	28.9±1.2	27.0±1.7	28.6±2.0	0.469
	ΔCt	−8.1±0.4	−7.1±0.8	−5.8±2.1	−5.6±2.1	0.421

Data are presented as mean±standard deviation. Ct_input denotes the threshold cycle of the input portion without methylated DNA enrichment. Ct_MBD denotes the threshold cycle of the methylated DNA enriched portion. The delta (Δ) threshold cycle (Ct) value was calculated as ΔCt = Ct_input - Ct_MBD. The values were compared using robust one-way analysis of variance (ANOVA), the post hoc Tamhane’s T2 test for multiple comparisons. In post hoc analysis, statistical significance (P < 0.05) is presented as follows: ^aTrisomy 21 placenta versus pregnant women blood; ^bTrisomy 21 placenta versus non pregnant women blood; ^cNormal placenta versus pregnant women blood; ^dNormal placenta versus non pregnant women blood; ^†EP6 versus EP9; ^#EP7 versus EP9.

ISSN: 1755-8794